Extent of prophylactic postoperative radiotherapy after radical surgery of thoracic esophageal squamous cell carcinoma
- PMID: 18840135
- DOI: 10.1111/j.1442-2050.2007.00797.x
Extent of prophylactic postoperative radiotherapy after radical surgery of thoracic esophageal squamous cell carcinoma
Abstract
The aim of this study was to assess if the entire mediastinum (M), the bilateral supraclavicular area (S), and the left gastric area (L) should be all included in the irradiation volume. The clinical data of 204 patients with thoracic esophageal squamous cell carcinoma who had undergone prophylactic postoperative radiotherapy after radical surgery were retrospectively reviewed. They were classified into four groups: group A, 26 patients with irradiated M alone; group B, 139 patients with irradiated M + S; group C, 10 patients with irradiated M + L; and group D, 29 patients with irradiated M + S + L. The 5-year disease-free survival rates were 36% in group A, 31% in group B, 40% in group C and 44% in group D (chi2=3.05, P =0.39), respectively. Multivariate analysis revealed that the irradiated extent was not a significant influential factor (hazard ratio=0.84, 95% confidence interval, 0.69-1.03, P =0.10). None of 43 patients without the L irradiated and with disease in the upper and middle upper thirds (defined in middle third but with upper third invaded), and one of 83 patients without the L irradiated and with disease in the middle third only thoracic esophagus were shown to have abdominal lymph node metastasis. Supraclavicular lymph node metastasis in patients in the lower and middle lower thirds (defined in middle third but with lower third invaded) were, respectively, 1/43 and 1/18 whether the S was irradiated or not. It seems unnecessary that the L be irradiated when the primary site is in the upper, middle, and middle upper thirds of the thoracic esophagus after radical surgery. Similarly, S may be unnecessarily irradiated in the lower and middle lower thirds.
Similar articles
-
Number and location of positive nodes, postoperative radiotherapy, and survival after esophagectomy with three-field lymph node dissection for thoracic esophageal squamous cell carcinoma.Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):475-82. doi: 10.1016/j.ijrobp.2010.08.037. Epub 2010 Oct 8. Int J Radiat Oncol Biol Phys. 2012. PMID: 20934269
-
Pattern of relapse in surgical treated patients with thoracic esophageal squamous cell carcinoma and its possible impact on target delineation for postoperative radiotherapy.Radiother Oncol. 2010 Jul;96(1):104-7. doi: 10.1016/j.radonc.2010.04.029. Epub 2010 Jun 3. Radiother Oncol. 2010. PMID: 20605246
-
Prognostic factors of radiotherapy in patients with node-positive thoracic esophageal squamous cell carcinoma after radical surgery.Dis Esophagus. 2009;22(6):490-5. doi: 10.1111/j.1442-2050.2008.00936.x. Epub 2009 Jan 23. Dis Esophagus. 2009. PMID: 19191849
-
Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma.Ann Thorac Surg. 2004 Oct;78(4):1177-83. doi: 10.1016/j.athoracsur.2004.02.068. Ann Thorac Surg. 2004. PMID: 15464466 Review.
-
Comparison of the effect of postoperative radiotherapy with surgery alone for esophagus squamous cell carcinoma patients: A meta-analysis.Medicine (Baltimore). 2018 Nov;97(47):e13168. doi: 10.1097/MD.0000000000013168. Medicine (Baltimore). 2018. PMID: 30461614 Free PMC article. Review.
Cited by
-
Activated Mast Cells Combined with NRF2 Predict Prognosis for Esophageal Cancer.J Oncol. 2023 Jan 4;2023:4211885. doi: 10.1155/2023/4211885. eCollection 2023. J Oncol. 2023. PMID: 36644231 Free PMC article.
-
Exosomal lncRNA ZFAS1 regulates esophageal squamous cell carcinoma cell proliferation, invasion, migration and apoptosis via microRNA-124/STAT3 axis.J Exp Clin Cancer Res. 2019 Nov 27;38(1):477. doi: 10.1186/s13046-019-1473-8. J Exp Clin Cancer Res. 2019. PMID: 31775815 Free PMC article.
-
Propensity-matched study on locally advanced esophageal cancer: surgery versus post-operative radiotherapy.Radiat Oncol. 2024 Sep 27;19(1):130. doi: 10.1186/s13014-024-02528-0. Radiat Oncol. 2024. PMID: 39334405 Free PMC article.
-
A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.BMC Cancer. 2020 Feb 18;20(1):130. doi: 10.1186/s12885-020-6592-2. BMC Cancer. 2020. PMID: 32070309 Free PMC article. Clinical Trial.
-
Postoperative tumor bed radiation versus T-shaped field radiation in the treatment of locally advanced thoracic esophageal squamous cell carcinoma: a phase IIb multicenter randomized controlled trial.BMC Med. 2024 Nov 7;22(1):522. doi: 10.1186/s12916-024-03727-y. BMC Med. 2024. PMID: 39511550 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical